NCT06897046View on ClinicalTrials.gov

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

February 25, 2027

Study Completion Date

May 25, 2027

Conditions
Non-small Cell Lung Cancer (NSCLC)II-IIIB
Interventions
DRUG

QL1706

PD-1/CTLA-4

DRUG

QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed

PD-1/CTLA4 combined chemotherapy drugs

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06897046 - Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC | Biotech Hunter | Biotech Hunter